Understanding how HDAC6 affects breast cancer treatment responses
Official title: Investigating the Molecular Determinants Driving Response and Resistance to HDAC6 Targeted Therapy in Breast Cancer
Funded at Icahn School of Medicine at Mount Sinai · NIH-11049020 · Data updated 2026-11-12
This study is looking at how a protein called HDAC6 affects breast cancer treatment, hoping to find out which patients might do better with new therapies that target this protein, so they can get more effective care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 5, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $569,181 |
| NIH project number | 5R01CA274251-02 |
| Project ID | NIH-11049020 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with breast cancer who have tumors that depend on HDAC6 for their growth.
✕Less likely to help
Patients with breast cancer that does not rely on HDAC6 or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the role of histone deacetylase 6 (HDAC6) in breast cancer, focusing on how it influences the effectiveness of targeted therapies. By analyzing a large number of breast cancer samples, the researchers have identified a biomarker that helps determine which patients may benefit from HDAC6-targeted treatments. The study aims to improve treatment strategies by exploring the molecular mechanisms behind the anticancer effects of HDAC6 inhibitors in combination with other therapies. Patients with specific breast cancer profiles may be eligible for clinical trials testing these innovative treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with certain types of breast cancer.
How similar studies have gone: Previous research has shown promising results with HDAC6 inhibitors in breast cancer, indicating potential for success in this approach.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Silva, Jose M — Icahn School of Medicine at Mount Sinai
- Study coordinator: Silva, Jose M
Related research
Other NIH-funded projects on the same topics.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Overcoming Resistance to Targeted Therapy in Breast Cancer
Researchers are studying why some breast cancers stop responding to targeted therapies and what can be done to overcome this resistance.
-
PET scans to track glutamine use in triple-negative breast cancer
This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.
-
Making HDAC6-targeted treatments work better for breast cancer
This work looks at how blocking HDAC6 affects breast cancers and finds which patients are most likely to benefit.
-
Improving Targeted Therapy for Triple Negative Breast Cancer
This project aims to develop a new way to deliver targeted medicines directly to triple-negative breast cancer tumors using special RNA molecules.
-
Using PET imaging to understand glutamine metabolism in triple-negative breast cancer
This study is looking at how a substance called glutamine affects triple-negative breast cancer to find better ways to treat it, using special imaging to see how much glutamine is in the cancer cells and helping doctors choose the best therapies for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.